Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSGEU6)

Drug Name
JAB-3068 Drug Info
Synonyms SHP2-IN-6; SCHEMBL19704279; JAB3068; NSC827676; NSC-827676; HY-131132; CS-0129188; 2169223-48-5
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
132222602
TTD Drug ID
DMSGEU6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Protein-tyrosine phosphatase SHP-2 (PTPN11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
JAB-3312 DMNMV0D Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
TNO155 DMZ60X4 Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
BBP-398 DM572ZL Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
SAR442720 DMTAOPC Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
RLY-1971 DMUT4YZ Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
PF-07284892 DMQ6F8X Aggressive cancer 2A00-2F9Z Phase 1 [7]
A380 DMXOZDP Aggressive cancer 2A00-2F9Z Phase 1 [8]
RG6433 DMZM06U Aggressive cancer 2A00-2F9Z Phase 1 [9]
NSC-87877 DMEYKXL Discovery agent N.A. Patented [10]
Dodecane-Trimethylamine DMUPMCZ Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Protein-tyrosine phosphatase SHP-2 (PTPN11) TT7WUAV PTN11_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03518554) A First in Human, Dose Escalation Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of AbbVie.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT04528836) First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
5 Clinical pipeline report, company report or official report of Revolution Medicines.
6 Clinical pipeline report, company report or official report of Relay Therapeutics.
7 SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy. Cancer Discov. 2023 Aug 4;13(8):1789-1801.
8 Clinical pipeline report, company report or official report of Klus Pharma
9 Clinical pipeline report, company report or official report of Roche
10 Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J Med Chem. 2008 Aug 28;51(16):4948-56.
11 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.